Related Experiment Videos
Tetrodotoxin: sodium channel specific anti-arrhythmic activity
H J Duff1, R S Sheldon, N J Cannon
1Department of Medicine, University of Calgary, Alberta, Canada.
Cardiovascular Research
|November 1, 1988
Summary
Selective sodium channel blockade with tetrodotoxin demonstrated anti-arrhythmic effects in a rabbit model of malignant ventricular arrhythmias. This finding suggests that blocking only sodium channels is sufficient for treating these dangerous heart rhythm disturbances.
Area of Science:
- Cardiovascular Pharmacology
- Cardiac Electrophysiology
- Arrhythmology
Background:
- Many Class I anti-arrhythmic drugs exhibit polyspecific channel blockade, affecting sodium, calcium, and potassium channels.
- The precise contribution of selective sodium channel blockade to anti-arrhythmic activity remains an area of investigation.
Purpose of the Study:
- To test the hypothesis that selective sodium channel blockade, without affecting calcium or potassium channels, confers anti-arrhythmic activity.
- To evaluate the efficacy of tetrodotoxin, a selective sodium channel blocker, in treating malignant ventricular arrhythmias.
Main Methods:
- A rabbit heart in vitro model was used, inducing ventricular fibrillation via critical extrastimuli after ischemic injury.
- Preparations were randomized to receive either tetrodotoxin or a vehicle control.
- Electrophysiological parameters, including effective refractory period and conduction time, were measured.
Main Results:
- Vehicle-treated preparations uniformly developed ventricular fibrillation.
- Tetrodotoxin exhibited dose-dependent protection against fibrillation, with complete prevention at concentrations above 3 micromolar.
- Tetrodotoxin increased ventricular effective refractory period and infarct zone conduction time, correlating with anti-arrhythmic effects.
Conclusions:
- Selective blockade of cardiac sodium channels by tetrodotoxin is sufficient to produce significant anti-arrhythmic activity.
- These findings support the development of anti-arrhythmic agents targeting sodium channels specifically for treating malignant ventricular arrhythmias.